Jianying C. Xi

No.12 Middle Wulumuqi Road
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

Journal: JAMA neurology

Published: July 27, 2026

Real-world implications of efgartigimod in managing refractory myasthenia gravis.

Real-world implications of efgartigimod in managing refractory myasthenia gravis.

Journal: Expert opinion on biological therapy

Published: May 20, 2026

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China.

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China.

Journal: Frontiers in immunology

Published: January 26, 2026

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.

Journal: Frontiers in immunology

Published: January 12, 2026

Case Report: Anti-cavin-4-positive immune-mediated rippling muscle disease co-occurring with isolated ocular myasthenia gravis.

Case Report: Anti-cavin-4-positive immune-mediated rippling muscle disease co-occurring with isolated ocular myasthenia gravis.

Journal: Frontiers in immunology

Published: December 08, 2025

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.

Journal: European journal of neurology

Published: December 02, 2025

Phospho-MLKL Upregulation in Immune-Mediated Necrotizing Myopathy: Implications for Disease Pathophysiology and Diagnosis.

Phospho-MLKL Upregulation in Immune-Mediated Necrotizing Myopathy: Implications for Disease Pathophysiology and Diagnosis.

Journal: Neuropathology : official journal of the Japanese Society of Neuropathology

Published: December 01, 2025

Cascading reactive oxygen species storm amplification via a soft X-ray-activated dual-photosensitizer nanoplatform for efficient photodynamic therapy.

Cascading reactive oxygen species storm amplification via a soft X-ray-activated dual-photosensitizer nanoplatform for efficient photodynamic therapy.

Journal: Journal of colloid and interface science

Published: October 30, 2025

Good's syndrome and infections in a large retrospective cohort of thymoma.

Good's syndrome and infections in a large retrospective cohort of thymoma.

Journal: Frontiers in immunology

Published: October 27, 2025

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: October 11, 2025

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

Journal: European journal of neurology

Published: October 06, 2025

Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.

Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.

Journal: Frontiers in immunology

Published: October 01, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026